Ovid Therapeutics (OVID) Deferred Taxes (2016 - 2017)
Ovid Therapeutics' (OVID) quarterly Deferred Taxes came in at $725657.0 in Q3 2017, up 6.49% quarter-over-quarter from $681458.0 in Q2 2017.
Powered by 
Analysis
Ovid Therapeutics (OVID) Deferred Taxes (2016 - 2017) Analysis & Trends
Ovid Therapeutics (OVID) has reported Deferred Taxes for 2 consecutive years, with $725657.0 the latest figure, recorded in Q3 2017.
- For the quarter ending Q3 2017, Deferred Taxes changed N/A year-over-year to $725657.0; the trailing twelve-month figure through Dec 2017 stood at $229000.0 (changed N/A YoY), and the FY2017 full-year result was $229000.0, up 200.0% from the prior year.
- Deferred Taxes rose to $725657.0 in Q3 2017 per OVID's latest filing, from $681458.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $725657.0 in Q3 2017 and bottomed at -$1.2 million in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -1.32 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 115.62 Mn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 725,657.00 |
| Jun 30, 2017 | 681,458.00 |
| Mar 31, 2017 | -1.18 Mn |
| Jun 30, 2016 | 574,755.00 |
| Mar 31, 2016 | -595,858.00 |